C9-ASO

N/A

Report date: 2025/01/26 18:40:07
NME

Base Information

Drug NameC9-ASO
Drug Alias NameC9orf72 antisense oligonucleotide therapy (Perelman School of Medicine/Mayo Clinic)TDP-43 aggregation inhibitors (Perelman School of Medicine/Mayo Clinic)C9-ASO
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionGuanine nucleotide exchange C9orf72 inhibitors
TargetsGuanine nucleotide exchange C9orf72
Therapy Area/IndicationsAmyotrophic Lateral SclerosisFrontotemporal Dementia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pennsylvania Perelman School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesMayo ClinicUniversity Of Pennsylvania Perelman School Of Medicine
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral SclerosisFrontotemporal Dementia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A